Is Novocure Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Novocure Ltd (NVCR) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Novocure Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Novocure Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Novocure Ltd?

Muslim investors may consider investing in Novocure Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Novocure Ltd classified as HALAL?

Musaffa determines the Shariah status of Novocure Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Novocure Ltd updated?

The Shariah compliance status of Novocure Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Novocure Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Novocure Ltd?

You can check the latest Shariah compliance status of Novocure Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NVCR Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: May 08, 2026

Report Source: 2026 1st Quarter Report

Novocure Ltd. Stock Analysis NVCR

United States Health Care Small Cap Report: Q1, 2026

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

Key Statistics of Novocure Ltd (NVCR)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$17.44$18.25

Today's Open

$17.82

Volume

1.41M

P/E Ratio (TTM)

52 Week Range

$9.82$20.06

Market Cap

1.84B

Avg. Volume

1.88M

Dividend Yield

Financial Metrics & Statements of Novocure Ltd (NVCR)

FAQ's for Novocure Ltd (NVCR)

According to Musaffa’s Shariah screening methodology, Novocure Ltd (NVCR) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.